Purpose Pharmacogenomic (PGx) testing provides genetic information that supports precision medicine use to improve efficacy and safety. A pharmacist-led PGx service was implemented to help providers manage drug–gene interactions.Summary A pharmacist-led PGx service had PGx pharmacist conducted chart reviews to identify and make management recommendations for the drug–gene interactions, which were shared with relevant providers. A quality improvement project was performed to assess the effectiveness of implementation. PGx chart review notes written by pharmacy from May 2024 to November 2024 were reviewed. Ninety-eight patients were included in this project. After reviewing the PGx pharmacist’s recommendations, providers managed 61% of the patients who had drug–gene interactions, where management was defined as a provider documenting their plans for the interactions in their notes. This is a significant improvement compared to pre-intervention data (from November 2023 to April 2024), where only 10% of interactions were managed by a provider. Not all drug–gene interactions (32%, 22/68) were associated with the specialty of the PGx ordering provider.Conclusion The pharmacist-led PGx service led to a six‑fold increase in healthcare provider-managed drug–gene interactions. The PGx pharmacist’s recommendations increased providers’ awareness of the drug–gene interactions.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: